Lumexa Imaging initiated with a Buy at Deutsche Bank

Deutsche Bank initiated coverage of Lumexa Imaging (LMRI) with a Buy rating and $22 price target The firm says Lumexa is the second-largest independent diagnostic testing facility operator in the U.S. The company’s growth drivers include share gains versus hospital outpatient via referral channels and direct-to-consumer marketing as well as an increasing advanced imaging mix, the analyst tells investors in a research note.